Understanding these interactions underscores the potential of epigenetic therapeutic strategies or adjuvants aimed at restoring immune competence (such as mucosal IFN responses) or limit receptor expression to mitigate early viral spread, thereby offering insights into the long-term immunological consequences of COVID-19. Here, IFNA1 is linked to COVID-19.